Olatorepatide (HS-20094)
A Chinese dual incretin agonist with Phase 3 results in the same range as tirzepatide, now partnered with Regeneron for markets outside China.
Investigational compounds, read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
Olatorepatide, coded HS-20094, is a once-weekly dual GLP-1/GIP receptor agonist from Hansoh Pharma, with Regeneron holding rights outside China. In the Phase 3 LIGHTEN trial in China, 604 participants lost 12.5%, 17.5%, and 19.3% of body weight at 5, 10, and 15 mg over 48 weeks, against 2.7% on placebo. Pooled rates of nausea and vomiting were 7.8% and 4.9%. China's regulator accepted an approval filing in June 2026, and the full data were presented at EASD in October 2026.
- Class
- Dual GLP-1/GIP receptor agonist, once weekly
- Sponsor
- Hansoh Pharma; Regeneron outside China
- Stage
- Phase 3 complete in China; approval filing accepted June 2026
- Target
- Obesity
What it is
Olatorepatide acts on the same two receptors as tirzepatide, GLP-1 and GIP, and is given once a week. Hansoh describes it as "dual-biased", meaning it is designed to favour particular signalling pathways inside the cell after binding its receptors. That design claim comes from the company and has not been shown to produce a clinical advantage.
It belongs to a fast-growing group of Chinese incretin drugs, alongside mazdutide, already approved in China, and ribupatide, now in global Phase 3. Regeneron's licence makes it one of the Chinese candidates most likely to reach Western markets.
Current research status
Headline results from the Phase 3 LIGHTEN trial were first released in March 2026, and China's regulator accepted a marketing application in June 2026. The full data were presented as a late-breaking oral presentation at EASD, announced October 2, 2026.
Regeneron had said it planned a global Phase 3 programme in 2026, though the EASD release did not mention one. Olatorepatide is not approved anywhere yet.
Mechanistic rationale
The pharmacology follows the tirzepatide model. GLP-1 receptor activation reduces appetite and slows stomach emptying, and GIP receptor activation appears to add to the weight loss and may improve tolerability. Biased agonism is an active area of incretin research, built on the idea that favouring some intracellular pathways over others could separate benefits from side effects. Whether that works in practice is not settled for any drug in the class.
Available evidence
Why it's interesting
Nearly 20% weight loss at 48 weeks places olatorepatide in the same range as the leading approved drugs, with a side-effect profile that looks favourable on these numbers. A credible partner in Regeneron gives it a route outside China.
Regeneron is also building a muscle-preservation programme around trevogrumab, which reported Phase 2 results in October 2026. Pairing an incretin with a muscle-sparing antibody is a strategy to watch.
Limitations & risks
The trial was run in China, where obesity is defined at lower body-mass thresholds and baseline weights tend to be lower than in Western trials. That makes direct comparison with SURMOUNT-1 or other Western trials unreliable. A global Phase 3 would be needed for approval in the US or Europe, and its timing is unclear.
The "dual-biased" description is a design rationale, not an established clinical benefit, and 48 weeks is shorter than the main tirzepatide and semaglutide trials.
Community discussion notes
Olatorepatide is rarely discussed in Western peptide communities, though the Chinese incretin wave is beginning to draw attention. It is not approved and not available outside clinical trials.
Where it fits in the field
Olatorepatide is one of the strongest Chinese incretin candidates: a completed Phase 3 with tirzepatide-range weight loss, a pending Chinese filing, and a Western partner. The open questions are whether its results replicate in a global population and whether its biased-signalling design delivers a real tolerability advantage.
Frequently asked questions
What is olatorepatide?
A once-weekly dual GLP-1/GIP receptor agonist from Hansoh Pharma, the same receptor targets as tirzepatide. Regeneron holds the rights outside China.
How does 19.3% compare with tirzepatide?
It is in a similar range, but the trials cannot be compared directly. LIGHTEN was run in China over 48 weeks, and differences in population and trial design make cross-trial comparisons unreliable.
Will it come to the US?
Possibly, through Regeneron. That would require a global Phase 3 programme, and its timing had not been confirmed as of October 2026.
Is olatorepatide available?
No. A marketing application was accepted in China in June 2026, but it is not approved anywhere.
References
- Hansoh Pharma. Phase 3 data of olatorepatide presented at EASD: 19.3% weight loss at week 48. October 2026. https://www.webdisclosure.com/press-release/193-weight-loss-at-week-48-phase-data-of-olatorepatide-hansohs-dualbiased-glp1gip-agonist-presented-at-easd-DXlO26IS9vw
- Fierce Biotech. Regeneron's obesity drug shows Zepbound-level efficacy in Phase 3. 2026. https://www.fiercebiotech.com/biotech/regenerons-obesity-drug-shows-zepbound-efficacy-phase-3